

N.B. English translation is for convenience purposes only

The Board of Directors' of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, proposal to amend the articles of association (item 6)

The Board of Directors proposes that the Extraordinary General Meeting resolves to amend the limits of the share capital and the number of shares in the articles of association. Item 4 in the articles of association is proposed to be amended from:

“The share capital shall be not less than SEK 1,500,000 and not more than SEK 6,000,000.” to:

“The share capital shall be not less than SEK 2,500,000 and not more than SEK 10,000,000.”

Item 5 in the articles of association is proposed to be amended from:

“The number of shares shall be not less than 30,000,000 and not more than 120,000,000.” to:

“The number of shares shall be not less than 50,000,000 and not more than 200,000,000.”

Further, the Board of Directors proposes that the Extraordinary General Meeting resolves to amend the CSD-clause in the articles of association. The amendment is implemented to update the articles of association in accordance with applicable legislation. Item 12 in the articles of association is proposed to be amended from:

“The shareholder or trustee who is, on the record date, entered in the share register and recorded in an CSD-register, in accordance with Chapter 4 of the Financial Instruments (Accounts) Act (1998:1479), or registered in an CSD-account, in accordance with Chapter 4 Section 18 Paragraph 6–8 of the Financial Instruments (Accounts) Act (1998:1479), shall be presumed to be entitled to exercise the rights set forth in Chapter 4 Section 39 of the Swedish Companies Act (2005: 551).” to:

“The company’s shares shall be registered in a CSD-register in accordance with the Swedish Central Securities Depositories and Financial Instruments (Accounts) Act (SFS 1998:1479).”

The CEO, or any other person appointed by the Board of Directors, shall have the right to make such minor adjustments that may be required in order to register the resolution with the Swedish Companies Registration Office.

A valid resolution in accordance with the Board of Directors' proposal according to above requires the approval of shareholders representing at least two thirds of the votes cast and the shares represented at the Extraordinary General Meeting.

Lund in February 2018

NeuroVive Pharmaceutical AB (publ)

The Board of Directors